Cytokeratin 19 Antibody [A53-B/A2.26]

Signal Transduction

WB: 1-2 ug/ml

Flow Cytometry: 0.5-1 ug/million cells

IF: 1-2 ug/ml

IHC (FFPE): 0.5-1 ug/ml for 30 min at RT (1)

Prediluted format : incubate for 30 min at RT (2)

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the Cytokeratin 19 antibody to be titered up or down for optimal performance.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate Buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Monoclonal

IgG2a, kappa

PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Aliquot and Store at 2-8˚ C. Avoid freez-thaw cycles.

None

3880

KRT19

Homo sapiens

This antibody is specific to the rod domain of human Cytokeratin 19 (CK19), a polypeptide of 40kDa. Its epitope maps between amino acid 312-335. Cytokeratin 19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Cytokeratin 19 antibody reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Cytokeratin 19 antibody is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Western blot testing of human samples using of Cytokeratin 19 antibody (A53-B/A2.26).